# US 2014/0271488 A1 · Chiral compounds of varying conformational rigidity and methods of synthesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271488 A1
- Document ID: US20140271488A1
- Status: Published application
- Kind: A1
- Application number: 14/343,426
- Filed: 2012-09-07
- Published: 2014-09-18
- Earliest claimed: 2011-09-07
- Assignees: The Scripps Research Institute
- Applicants: The Scripps Research Institute
- Inventors: Glenn C. Micalizio; Thomas Kodadek; Mohosin Sarkar
- Web page: https://patentgrep.com/patent/US20140271488A1

## CPC

- C07K 5/08: Tripeptides
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 38/06: Tripeptides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07B 53/00: Asymmetric syntheses
- C07C 51/00: Preparation of carboxylic acids or their salts, halides or anhydrides (of acids by hydrolysis of oils, fats or waxes C11C)
- C07C 57/52: containing halogen
- C07C 57/54: Halogenated acrylic or methacrylic acids
- C07C 57/60: having unsaturation outside the rings
- C07C 57/64: Acyl halides
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 405/14: containing three or more hetero rings
- C07K 5/0205: {containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof}
- C07K 5/0804: {and aliphatic}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- C07B 2200/07: Optical isomers
- C07B 2200/11: Compounds covalently bound to a solid support
- G01N 2800/7028: Cancer
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Synthesis of compounds having varying degrees of conformational rigidity is obtained via a low cost, high yield and efficient synthetic reactions. The library of compounds is structurally diverse having at least one or more chiral centers and providing large numbers of compounds having building block diversity and substantial scaffold diversity. The compounds further provide a novel method for obtaining candidate therapeutic agents for prevention, treatment or diagnosis of diseases.

## Claims

### Claim 1

A method of synthesizing a chiral monomer comprising:
obtaining a stereodefined allylic alcohol via a stereoselective aldol reaction or a related transformation reaction and proceeding via stereoselective allylic transposition of the resulting allylic alcohol; and
converting the resulting rearranged product to a chiral acid having a general structure of Formula I′:

### Claim 2 (depends on 1)

The method of claim 1, wherein R1 and R2 comprise a molecular architecture compatible with the synthesis of Formula I′ or introduced after synthesis of a central pentenoic acid of Formula I′.

### Claim 3 (depends on 1)

The method of claim 1, wherein two or more monomers of Formula I′ are optionally oligomerized, the oligomerization of Formula I′ proceeding via a 1- or 2-directional homologation or functionalization of Formula I′.

### Claim 4 (depends on 3)

The method of claim 3, wherein X and Y comprise any molecule compatible with the oligomerization of Formula I′.

### Claim 5 (depends on 2)

The method of claim 2, wherein an oligomer or polymer of Formula I′ comprises homogeneous monomers, heterogeneous monomers or combinations thereof.

### Claim 6

A compound comprising a monomer set forth in Formula I:
wherein, X and Y comprise any molecular motifs or functional groups compatible with oligomerization of two or more monomers of Formula I.

### Claim 7 (depends on 6)

The compound of claim 6, wherein an oligomeric compound comprises at least two or more monomers represented by Formula I comprising a chiral center in an R configuration, an S configuration or multiple combinations thereof.

### Claim 8 (depends on 6)

The compound of claim 6, wherein the monomer of Formula I is a pentenoic amide.

### Claim 9 (depends on 8)

The compound of claim 8, wherein the pentenoic amide is a central N-substituted 5-amino-2,4-dialkyl-3-pentenoic amide.

### Claim 10 (depends on 6)

The compound of claim 6, wherein a monomer of Formula I comprises substitutions which maintain conformational control about a β,γ-unsaturated carbonyl and minimize allylic strain.

### Claim 11 (depends on 6)

The compound of claim 6, wherein monomers or oligomers of Formula I comprise substitutions having varying degrees of flexibility imparted by monomers comprising the backbone.

### Claim 12 (depends on 6)

The compound of claim 6, wherein uni- or bidirectional functionalization of Formula I produces a higher molecular weight compound comprising Formula I having a structure whereby conformation is controlled by minimization of A-1,3 strain inherent to a substituted β,γ-unsaturated carbonyl.

### Claim 13 (depends on 12)

The compound of claim 12, wherein the higher molecular weight compound of Formula I comprises oligomers having repeating units of Formula I and/or repeating monomers of Formula I having different substitutions R1 and R2, wherein R1 and R2 comprise any molecular architecture capable of forming a bond with the monomers or oligomers of Formula I.

### Claim 14 (depends on 13)

The compound of claim 13, wherein R1 and R2 independently comprise OR3, NHR4, NR4R5, halide, alkyl, linear alkyl, branched alkyl, heteroatom-substituted alkyl, unsaturated and polyunsaturated linear and branched hydrocarbons, alkenyl, cycloalkyl, aryl, heteroaryl, heteroaryl, heterocycloalkyl, heteroatom-substituted unsaturated and polyunsaturated linear and branched hydrocarbons, cycloalkyl, heteroatom-substituted cycloalkyl, saturated and unsaturated heterocycles, substituted cycloalkyl, substituted and unsubstituted aromatic, substituted and unsubstituted heteroaromatic; R3 independently comprises H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, NR4R5, carboxyl, heterocycloalkyl; and, R4 independently comprises H, OR3, alkyl, aryl, or heteroaryl.

### Claim 15 (depends on 6)

The compound of claim 6, wherein X independently comprises OR3, NHR4, NR4R5, H, halide, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heteroaryl, heterocycloalkyl; R3 independently comprises amide, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, NR4R5, carboxyl, heterocycloalkyl; R4 independently comprises H, OR4, alkyl, aryl, heteroaryl; *C is a chiral center [(R) or (S)]; R1 independently comprises alkyl, aryl, heteroaryl, alkenyl, OR4; R2 independently comprising alkyl, cycloalkyl, aryl, heteroaryl, alkynyl, alkenyl, heterocycloalkyl; Y independently comprises a halide, NHR4, NR4R5, OH, OR3, or C(O)X.

### Claim 16

A method of identifying a candidate therapeutic agent, comprising:
screening a library comprising one or more monomers, oligomers, or polymers of Formula I:
contacting a biological sample, cell, tissue, or molecule in solution or attached to a solid or semi-solid support, with a compound of Formula I;
assaying for any desired therapeutic effects; and,
identifying a candidate therapeutic agent.

### Claim 17 (depends on 16)

The method of claim 16, wherein for Formula I: X independently comprises OR3, NHR4, NR4R5, H, halide, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heteroaryl, heterocycloalkyl; R3 independently comprises amide, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, NR4R5, carboxyl, heterocycloalkyl; R4 independently comprises H, OR4, alkyl, aryl, heteroaryl; *C is a chiral center [(R) or (S)]; R1 independently comprises alkyl, aryl, heteroaryl, alkenyl, OR4; R2 independently comprising alkyl, cycloalkyl, aryl, heteroaryl, alkynyl, alkenyl, heterocycloalkyl; Y independently comprises a halide, NHR4, NR4R5, OH, OR3, or C(O)X.

### Claim 18 (depends on 16)

The method of claim 16, wherein desired therapeutic effects comprise: tumor cell death, inhibition of viral replication, cytolysis of virally infected cells, modulation of receptors, modulation of growth factors, modulation of cytokines, modulation of cellular factors, modulation of immune cells, anti-bacterial effects, anti-parasitic effects or combinations thereof.

### Claim 19

A pharmaceutical composition comprising a compound having a structure of Formula I:

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein X and Y comprise any molecular motif or functional group compatible with oligomerization of two or more monomers of Formula I.

### Claim 21 (depends on 19)

The pharmaceutical composition of claim 19, wherein R1 and R2 comprise any molecular architecture capable of forming a bond with monomers or oligomers of Formula I.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein R1 and R2 independently comprise OR3, NHR4, NR4R5, halide, alkyl, linear alkyl, branched alkyl, heteroatom-substituted alkyl, unsaturated and polyunsaturated linear and branched hydrocarbons, alkenyl, cycloalkyl, aryl, heteroaryl, heteroaryl, heterocycloalkyl, heteroatom-substituted unsaturated and polyunsaturated linear and branched hydrocarbons, cycloalkyl, heteroatom-substituted cycloalkyl, saturated and unsaturated heterocycles, substituted cycloalkyl, substituted and unsubstituted aromatic, substituted and unsubstituted heteroaromatic; R3 independently comprises H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, NR4R5, carboxyl, heterocycloalkyl; and, R4 independently comprises H, OR3, alkyl, aryl, or heteroaryl.

### Claim 23 (depends on 19)

The pharmaceutical composition of claim 19, wherein X independently comprises OR3, NHR4, NR4R5, H, halide, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heteroaryl, heterocycloalkyl; R3 independently comprises amide, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, NR4R5, carboxyl, heterocycloalkyl; R4 independently comprises H, OR4, alkyl, aryl, heteroaryl; *C is a chiral center [(R) or (S)]; R1 independently comprises alkyl, aryl, heteroaryl, alkenyl, OR4; R2 independently comprising alkyl, cycloalkyl, aryl, heteroaryl, alkynyl, alkenyl, heterocycloalkyl; Y independently comprises a halide, NHR4, NR4R5, OH, OR3, or C(O)X.

### Claim 24

A compound comprising:

### Claim 25

A compound of Formula I comprising a monomer set forth in Formula I:
wherein, X and Y comprise any molecular motif or functional group compatible with oligomerization of monomers of Formula I; and, one or more monomers of an oligomer of Formula I are conjugated to a cytotoxic agent or detectable label.

### Claim 26 (depends on 25)

The compound of claim 25, wherein R1 and R2 comprise any molecular architecture capable of forming a bond with monomers or oligomers of Formula I.

### Claim 27 (depends on 26)

The compound of claim 26, wherein R1 and R2 independently comprise OR3, NHR4, NR4R5, halide, alkyl, linear alkyl, branched alkyl, heteroatom-substituted alkyl, unsaturated and polyunsaturated linear and branched hydrocarbons, alkenyl, cycloalkyl, aryl, heteroaryl, heteroaryl, heterocycloalkyl, heteroatom-substituted unsaturated and polyunsaturated linear and branched hydrocarbons, cycloalkyl, heteroatom-substituted cycloalkyl, saturated and unsaturated heterocycles, substituted cycloalkyl, substituted and unsubstituted aromatic, substituted and unsubstituted heteroaromatic; R3 independently comprises H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, NR4R5, carboxyl, heterocycloalkyl; and, R4 independently comprises H, OR3, alkyl, aryl, or heteroaryl.

### Claim 28 (depends on 25)

The compound of claim 25, wherein X independently comprises OR3, NHR4, NR4R5, H, halide, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heteroaryl, heterocycloalkyl; R3 independently comprises amide, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, NR4R5, carboxyl, heterocycloalkyl; R4 independently comprises H, OR4, alkyl, aryl, heteroaryl; *C is a chiral center [(R) or (S)]; R1 independently comprises alkyl, aryl, heteroaryl, alkenyl, OR4; R2 independently comprising alkyl, cycloalkyl, aryl, heteroaryl, alkynyl, alkenyl, heterocycloalkyl; Y independently comprises a halide, NHR4, NR4R5, OH, OR3, or C(O)X.

### Claim 29 (depends on 25)

The compound of claim 25, wherein a cytotoxic agent comprises: a toxin, radioactive molecule, chemotherapeutic agent, an inhibitor of replication, or combinations thereof.

### Claim 30 (depends on 25)

The compound of claim 25, wherein the detectable label comprises: a fluorescent molecule, radioactive molecule, a metal, or dye.

### Claim 31

A method of treating a hematopoietic malignancy in vivo, comprising: administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising at least one compound comprising:
a monomer or oligomer of a monomer set forth in Formula I:
wherein, X and Y comprise any molecular motifs or functional groups compatible with oligomerization of two or more monomers of Formula I,
wherein one or more monomers of an oligomer of Formula I are conjugated to one or more cytotoxic agents or detectable label and specifically binds to a hematopoietic malignant cell; and, treating the hematopoietic malignancy.

### Claim 32 (depends on 31)

The method of claim 31, wherein the hematopoietic malignancy comprises: B cell malignancies or neoplasms, chronic myeloproliferative diseases, myelodysplastic/myeloproliferative diseases, myelodysplastic syndromes, acute myeloid leukemias, B cell neoplasms, T-cell and NK-cell neoplasms, Hodgkin's lymphoma, histiocytic and dendritic cell neoplasms or mastocytosis.

### Claim 33 (depends on 32)

The method of claim 32, wherein the B cell malignancy comprises: B cell chronic lymphocytic leukemia (B-CLL), B cell lymphomas, aggressive B-cell lymphoma, Hodgkin's disease, B cell non-Hodgkin's lymphoma (NHL), lymphomas, Waldenstrom's macroglobulinaemia (lymphoplasmacytic lymphoma or immunocytoma), central nervous system lymphomas, leukemias, acute lymphoblastic leukemia (ALL), hairy cell leukemia, chronic myoblastic leukemia), myelomas, multiple myeloma), small lymphocytic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, solitary plasmacytoma of bone, extraosseous plasmacytoma, extra-nodal marginal zone B cell lymphoma of mucosa-associated (MALT) lymphoid tissue, nodal marginal zone B cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, Burkitt's lymphoma/leukemia, grey zone lymphoma, B cell proliferations of uncertain malignant potential, lymphomatoid granulomatosis, and post-transplant lymphoproliferative disorder.

### Claim 34 (depends on 31)

The method of claim 31, whereby the B cell malignancy is B-CLL.

### Claim 35 (depends on 31)

The method of claim 31, further comprising administering to a patient a chemotherapeutic agent or radiotherapy.

### Claim 36

A method of diagnosing a hematopoietic malignancy comprising administering to a patient, or contacting a biological sample in vitro with a compound comprising:
a monomer or oligomer of a monomer set forth in Formula I:
wherein, X and Y comprise any molecular motifs or functional groups compatible with oligomerization of two or more monomers of Formula I,
wherein one or more monomers of an oligomer of Formula I are conjugated to a detectable label and the compound specifically binds to a hematopoietic malignant cell in vivo or in vitro; and, diagnosing a hematopoietic malignancy.

### Claim 37 (depends on 36)

The method of claim 36, wherein the hematopoietic malignancy is B cell chronic lymphocytic leukemia (B-CLL).

### Claim 38

A method of modulating an immune cell disease or disorder comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising at least one compound comprising:
a monomer or oligomer of a monomer set forth in Formula I:
wherein, X and Y comprise any molecular motifs or functional groups compatible with oligomerization of two or more monomers of Formula I,
wherein one or more monomers of an oligomer of Formula I are conjugated to one or more agents and specifically binds to an immune cell receptor or ligand and modulates the immune cell mediated disease or disorder.

### Claim 39 (depends on 38)

The method of claim 38, wherein the immune cell disease or disorder comprises: autoimmune diseases, inflammatory diseases, transplantation rejection, lymphoproliferative diseases, allergies, neuroinflammatory diseases and disorders thereof.
